entertainment -WSS

entertainment

author：entertainment 2025-10-02 21:05:13 - browse：926

Amedisys -- Hospital coverage from STAT — Option Care Health is buying Amedisys, creating a national company that specializes in almost all types of home care. Wikimedia Commons

Option Care Health is buying Amedisys in an all-stock merger valued at $3.6 billion, creating a national company that specializes in almost all types of home care that can be provided from cradle to grave.

Health insurance companies, providers, and patients have pushed for more care to be handled at home instead of a hospital or post-acute facility, under the idea that quality home care saves money and is what patients want. Option Care’s deal for Amedisys marks another instance of this push, and comes just a few months after UnitedHealth Group closed on its $5.4 billion acquisition of LHC Group.

But Wall Street was not receptive to the deal, driving down Option Care’s stock by more than 25% on Thursday morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Adopting new red light myopia treatments may be short

focus

WSS

Will Ozempic

2023 STAT Wunderkinds: get to know the winners

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Readout LOUD: Venture capital, Gilead, and more M&A

How climate

Gene therapy for Afghan refugees’ infant will be fully covered

focus

entertainment

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Lawmakers consider Medicare pay reforms for doctors

Apple is now the first public company to be valued at $3 trillion

Why health workers in Gaza are injured or die at high rates

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Amgen, Regeneron, BGI Group and more

After affirmative action ruling, medical educators look to 'holistic review'

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Cancer drug shortages should be causing more outrage

FDA gives detailed accounting of AI

hotspot

Problems with a popular proposal to regulate AI in health care

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Lawmakers consider Medicare pay reforms for doctors

Cano Health’s bankruptcy is a warning for Medicare Advantage

Why Novartis is going to walk from its acquisition of MorphoSys

Beam Therapeutics to lay off 20% of its staff, re

entertainment

focus

explore

focus